argenx to acquire Forte Biosciences for $2.2 billion to expand its immunology portfolio
argenx has entered into a definitive agreement to acquire Forte Biosciences for $77 per share in cash, a transaction valued at approximately $2.2 billion. The acquisition is expected to close in the third quarter of 2026. This move strengthens the immunology portfolio of argenx by adding the lead asset of Forte Biosciences, FB102. FB102 is a first-in-class anti-CD122 antibody that has shown clinical proof-of-concept in treating vitiligo and celiac disease. The acquisition aligns with the 'Vision 2030' strategy of argenx, which aims to establish the company as a leading immunology innovator. Karen Massey, the Chief Executive Officer of argenx, stated that the addition of FB102 aligns perfectly with the company's playbook of compelling biology and strong clinical validation. Paul A. Wagner, Ph.D., the Chief Executive Officer and Chairperson of the Board of Forte Biosciences, expressed pride in the advancement of FB102 and noted that argenx is the ideal strategic partner to unlock its full potential across various autoimmune diseases.